# Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease

> **NCT02688842** · NA · COMPLETED · sponsor: **Shanghai MicroPort Medical (Group) Co., Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DEVICE:** Rapamycin target-eluting coronary stent systems (38mm)

## Key facts

- **NCT ID:** NCT02688842
- **Lead sponsor:** Shanghai MicroPort Medical (Group) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2016-01
- **Final completion:** 2021-01
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688842, "Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02688842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*